[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346209-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346209-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lung-cancer-screening-and-interception-innovative-approaches-for-enduring-challenges","Lung Cancer Screening and Interception: Innovative Approaches for Enduring Challenges","","Lung Cancer Screening and Interception: Innovative Approaches for Enduring Challenges presents a clinical oncology manuscript focused on lung cancer screening and interception strategies. The text includes publication details in Nature Reviews Clinical Oncology, author affiliations across major oncology and immunology institutions, and standard statements on author contributions. It also provides a competing interests section describing consulting, advisory roles, speaking engagements, research funding, and patent-related disclosures involving industry partners and clinical trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lung-cancer-screening-and-interception-innovative-approaches-for-enduring-challenges/346209/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lung-cancer-screening-and-interception-innovative-approaches-for-enduring-challenges/346209.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the document’s main topic?","Question",{"text":63,"@type":64},"It focuses on lung cancer screening and interception and the innovative approaches addressing enduring challenges in this area.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Where are the authors affiliated?",{"text":68,"@type":64},"Author affiliations span major cancer and immunology institutions, including the University of Texas MD Anderson Cancer Center and other international research centers and universities.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the document state about competing interests?",{"text":72,"@type":64},"It includes a detailed competing interests section listing consulting/advisory roles, research funding, and disclosures related to patents, clinical trials, and industry collaborations for specific authors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346209,1790193392,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Europe PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nEurope PMC Funders Group  \nAuthor Manuscript  \nNat Rev Clin Oncol. Author manuscript; available in PMC 2026 May 01.  \nPublished in final edited form as:  \nNat Rev Clin Oncol. 2026 May ; 23(5): 374–389. doi:10.1038/s41571-026-01131-4 .  \nLung Cancer Screening and Interception: Innovative Approaches for Enduring Challenges  \nJianjun Zhang 1,2,*,\\# , Matthew D. Park3 , Tej Pandya4,5,6 , Elaine Shum7 , Jia Wu 1,8 , Simon Heeke 1 , Ramin Salehi-Rad9 , Thomas U. Marron3 , Zhubo Wei 1 , Hui Li 1,8 , Torsten G. Blum 10 , Steven M. Dubinett9,\\# , Pan-Chyr Yang 11,\\# , Charles Swanton4,6,12,\\# , Miriam Merad3,\\#  \n1 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.  \n2 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.  \nThis work is licensed under a BY 4.0 International license.  \n*C\\# C-resseponniorencutheotors: Jianjun Zhang ([jzhang20@mdanderson.org](jzhang20@mdanderson.org)).  \nAuthor contributions  \nAll authors participated in the data collection, discussion of content and manuscript writing. All authors reviewed and/or edited the manuscript prior to submission.  \nCompeting interests  \nJ.Z. has acted as a consultant and/or adviser or speaker or received research funding from AstraZeneca, Beigene, Bicara, Bristol Myers Squibb, Catalyst, GenePlus, Helius, Hengrui, Innovent Biologics, Johnson & Johnson, Merck, Novartis, OrigMed, Oncohost, Roche, Summit, Takeda and Varian. T.P. has undertaken consultancy work for FutureHouse and been listed as inventors on a patent application (GB), that has been filed related to early detection of lung cancer and it is currently unpublished and remains within the priority year. P.C.Y. has acted as a consultant and/or adviser or speaker or received research funding from AstraZeneca, Boehringer Ingelheim, Pfizer, MSD, Eli Lilly, Roche, Merck, GSK, ONO Pharma, ACT Genomics. OBI Pharma, CHO Pharma, Onenessbio, DELTA Electronics. E.S. has reported advisory board/consulting from AstraZeneca, Genentech, Bristol Myers Squibb, Regeneron, Janssen, Boehringer Ingelheim and research funding (to the institution) from Delfi Diagnostics, AstraZeneca. T.U.M. has served on Advisory and/or Data Safety Monitoring Boards for Rockefeller University, Regeneron, AbbVie, Merck, EMD Serono, Geneos, AstraZeneca, Genentech, Glenmark, Arrowhead, G1 Therapeutics, NGMbio, DBV Technologies, Arcus, Fate, Ono, Storm, Replimmune, Avammune, Tubulis, NaturesToolbox, EvolveImmune, AN2 Therapeutics and Astellas, and has had research grants from the National Institutes of Health (NCI), the Cancer Research Institute, Regeneron, Genentech, Bristol-Myers Squibb, Merck, and Boehringer Ingelheim. He holds stock options in Natures Toolbox. S.M.D. has been on the scientific advisory boards for EarlyDiagnostics and LungLife AI, Inc. C.S. has acknowledged grants from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx Inc.—collaboration in minimal residual disease sequencing technologies), Ono Pharmaceutical, and Personalis. He is Chief Investigator for the AstraZeneca MeRmaiD 1 and 2 clinical  \ntrials and is the Steering Committee Chair. He is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s Scientific Advisory Board (SAB). He has received consultant fees from Achilles Therapeutics (also a SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, China Innovation Centre of Roche (CICoR;  \nformerly Roche Innovation Centre, Shanghai), Metabomed (until July 2022), Relay Therapeutics SAB member, Saga Diagnostics SAB member and the Sarah Cannon Research Institute. He has received honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Illumina, MSD, Novartis, Pfizer and Roche-Ventana. He has previously held stock options i","cbCait8ci9FlM2tv","https://ap.wps.com/l/cbCait8ci9FlM2tv","pdf",915305,33,"English","# Author Manuscript Metadata\n## Publication Information\n## Author Contributions\n## Competing Interests","[{\"question\":\"What is the document’s main topic?\",\"answer\":\"It focuses on lung cancer screening and interception and the innovative approaches addressing enduring challenges in this area.\"},{\"question\":\"Where are the authors affiliated?\",\"answer\":\"Author affiliations span major cancer and immunology institutions, including the University of Texas MD Anderson Cancer Center and other international research centers and universities.\"},{\"question\":\"What does the document state about competing interests?\",\"answer\":\"It includes a detailed competing interests section listing consulting/advisory roles, research funding, and disclosures related to patents, clinical trials, and industry collaborations for specific authors.\"}]","Lung Cancer Screening and Interception: Innovative Approaches for Enduring Challenges | PDF",1790060466,83,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d9e90da71178ae9b2eba6bb994b611f.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebd1e89ce78ee079e0ba75e93b228809.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cccdc79159de1a4a014ad37a8885c64d.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0502acefdfd1ba4f11a383e7e721a655.webp",980,1268]